NEW YORK – Precision medicine firm Genetron Health and Chia Tai Tianqing Pharmaceutical Group have entered an exclusive strategic partnership to exclusively comarket and copromote Genetron's HCCscreen – a blood-based early screening test for liver cancer — in hospitals across designated territories in China.
The parties intend to target high-risk individuals for hepatocellular carcinoma, which include hepatitis B virus carriers, as well as other liver disease patients, using CTTQ's experienced sales force and hospital relationships.